Clinical Trials /

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

NCT04561817

Description:

This is a phase II open label, non-randomized, study to evaluate the safety and efficacy of Ipatasertib (GDC-0068) in combination with paclitaxel in platinum-resistant recurrent epithelial ovarian cancer.

Related Conditions:
  • Fallopian Tube Carcinoma
  • Ovarian Carcinoma
  • Primary Peritoneal Carcinoma
Recruiting Status:

Withdrawn

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
  • Official Title: An Open Label Phase II Study to Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Clinical Trial IDs

  • ORG STUDY ID: GCO 19-2707
  • NCT ID: NCT04561817

Conditions

  • Ovarian Neoplasms

Interventions

DrugSynonymsArms
IpatasertibGDC-0068PI3K/AKT mutations (altered)
PaclitaxelPI3K/AKT mutations (altered)

Purpose

This is a phase II open label, non-randomized, study to evaluate the safety and efficacy of Ipatasertib (GDC-0068) in combination with paclitaxel in platinum-resistant recurrent epithelial ovarian cancer.

Detailed Description

      This is a phase II open label, non-randomized, study to evaluate the safety and efficacy of
      Ipatasertib (GDC-0068) in combination with paclitaxel in platinum-resistant recurrent
      epithelial ovarian cancer.

      The primary objective of the study is to determine - the safety and objective response rate
      of treatment with ipatasertib (GDC-0068) in combination with paclitaxel in platinum-resistant
      recurrent epithelial ovarian cancer at week 12 for two cohorts of patients: with PI3K/AKT
      mutations (altered) and without PI3K/AKT mutations (non-altered)

      About 39 patients will participate in the study and the accrual will take place over a course
      of 30 months Patients will be treated until disease progression and followed for 1 year
      thereafter.

      The two drugs are ipatasertib and paclitaxel.

        -  Ipatasertib will be given 400mg PO daily: day 1-21 of 28 day cycle

        -  Paclitaxel will be given 80mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle

      The study hypothesis is that the combination of Ipatasertib (GDC-0068) plus paclitaxel will
      safely induce a tumor response and increase the objective response rate in patients with
      platinum-resistant recurrent epithelial ovarian cancer, with or without PI3K/AKT mutations.

      This trial will enroll patients with platinum-resistant recurrent epithelial ovarian cancer.
      Given the relatively poor prognosis and limited treatment options for these patients, this
      population is considered appropriate for trials of novel therapeutic candidates. The
      benefit-risk ratio for ipatasertib in combination with paclitaxel is expected to be
      acceptable in this setting.
    

Trial Arms

NameTypeDescriptionInterventions
PI3K/AKT mutations (altered)Active ComparatorParticipants with recurrent epithelial ovarian cancer with PI3K/AKT mutations (altered)
  • Ipatasertib
  • Paclitaxel
Without PI3K/AKT mutations (non-altered)Active ComparatorParticipants with recurrent epithelial ovarian cancer without PI3K/AKT mutations (non-altered)
  • Ipatasertib
  • Paclitaxel

Eligibility Criteria

        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures, sampling and analyses

             o If a patient declines to participate in any voluntary exploratory research and/or
             genetic component of the study, there will be no penalty or loss of benefit to the
             patient and he/she will not be excluded from other aspects of the study

          -  Aged at least 18 years at time of signing informed consent

          -  A pathologic (histology or cytology) confirmed diagnosis of epithelial ovarian cancer,
             including fallopian or primary peritoneal cancer

             o low grade serous histology is excluded

          -  Radiographic evidence of recurrent epithelial ovarian cancer (ovarian, fallopian tube,
             or primary peritoneal cancer) that has become "platinum-resistant," defined as
             progression of disease within 6 months from the last dose of platinum-based
             chemotherapy, or platinum refractory

          -  Not a candidate for cytoreductive surgery

          -  Measurable disease (at least one lesion that can be accurately assessed repeatedly by
             CT or MRI) as evidenced on pre-treatment baseline CT of Chest/Abdomen/Pelvis, MRI, or
             PET/CT, or evaluable disease (defined as anything non-measurable- pleural effusions,
             lesions <1cm, etc).

          -  World Health Organization (WHO) performance status 0-1 with no deterioration over the
             previous 2 weeks and minimum life expectancy of 12 weeks

          -  Up to 3 lines of prior cytotoxic chemotherapy

          -  Previously received bevacizumab

          -  Has not received weekly paclitaxel-containing regimen, EXCEPT for in the front-line
             setting

             o Patients with prior paclitaxel reactions may be enrolled if they have been
             successfully re-treated with steroid pre-medication in the past

          -  Patients must use adequate contraceptive measures, should not be breast feeding and
             must have a negative pregnancy test prior to start of dosing (within 7 days) if of
             child-bearing potential or must have evidence of non-child-bearing potential by
             fulfilling one of the following criteria at screening:

               -  Post-menopausal defined as aged more than 50 years and amenorrhea for at least 12
                  months following cessation of all exogenous hormonal treatments

               -  Documentation of irreversible surgical sterilization by hysterectomy, bilateral
                  oophorectomy or bilateral salpingectomy but not tubal ligation

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per
             year during the treatment period and for 28 days after the last dose of study
             treatment. Women must refrain from donating eggs during this same period.

        Exclusion Criteria:

          -  Treatment with any of the following:

               -  Any investigational agents or study drugs from a previous clinical study within
                  28 days of the first dose of study treatment

               -  Any other chemotherapy, immunotherapy or anticancer agents within 14 days of the
                  first dose of study treatment

               -  Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2D6
                  within 2 weeks before the first dose of study treatment (3 weeks for St John's
                  Wort)

               -  Any prior exposure to Ipatasertib

          -  Major surgery (excluding placement of vascular access) within 4 weeks of the first
             dose of study treatment

          -  Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a
             limited field of radiation for palliation within 2 weeks of the first dose of study
             treatment

          -  With the exception of alopecia, any unresolved toxicities from prior therapy greater
             than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of
             starting study treatment

          -  Spinal cord compression or brain metastases unless asymptomatic, treated and stable
             and not requiring steroids for at least 2 weeks prior to start of study treatment

          -  Concurrent use of endocrine therapy

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic
             diseases, including active bleeding diatheses, or active infection including hepatitis
             B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic
             conditions is not required.

          -  Any of the following cardiac criteria:

               -  Any clinically important abnormalities in rhythm, known prolonged QTc, conduction
                  or morphology of resting ECG, complete left bundle branch block, third degree
                  heart block

               -  Experience of any of the following procedures or conditions in the preceding 6
                  months: coronary artery bypass graft, angioplasty, vascular stent, myocardial
                  infarction, angina pectoris, congestive heart failure NYHA Grade 2 or greater

               -  Uncontrolled hypotension - Systolic BP <90mmHg and/or diastolic BP <50mmHg

               -  Left ventricular ejection fraction (LVEF) below lower limit of normal for site

          -  Inadequate bone marrow reserve or organ function as demonstrated by any of the
             following laboratory values:

               -  Absolute neutrophil count < 1.5 x 109/L

               -  Platelet count < 100 x 109/L

               -  Hemoglobin < 9 g/L

               -  Alanine aminotransferase > 2.5 times the upper limit of normal (ULN)

               -  Aspartate aminotransferase > 2.5 times ULN

               -  Total bilirubin > 1.5 times ULN

               -  Creatinine >1.5 times ULN concurrent with creatinine clearance < 50 ml/min
                  (measured or calculated by Cockcroft and Gault equation); confirmation of
                  creatinine clearance is only required when creatinine is > 1.5 times ULN

               -  Proteinuria 3+ on dipstick analysis or >500mg/24 hours

               -  Sodium or potassium outside normal reference range for site

          -  Peripheral neuropathy grade 2 or greater

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
             swallow the formulated product or previous significant bowel resection that would
             preclude adequate absorption Ipatasertib

          -  History of hypersensitivity to Ipatasertib, or drugs with a similar chemical structure
             or class to Ipatasertib

          -  Clinically significant abnormalities of glucose metabolism as defined by any of the
             following:

               -  Diagnosis of type I or type II diabetes mellitus requiring insulin

               -  A baseline fasting glucose value of ≥ 200 mg/dL (fasting glucose value to be
                  obtained only if non-fasting glucose >200mg/dL)

               -  Glycosylated hemoglobin (HbA1C) >7.5%

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites

          -  Other malignancies within the past 3 years, with the exception of adequately resected
             basal or squamous carcinoma of the skin

          -  Clinically significant pulmonary symptoms or disease

          -  Judgment by the investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions and requirements
      
Maximum Eligible Age:90 Years
Minimum Eligible Age:18 Years
Eligible Gender:Female
Healthy Volunteers:No

Primary Outcome Measures

Measure:Objective response rate (ORR)
Time Frame:At the end of Cycle 1 (each cycle is 28 days)
Safety Issue:
Description:ORR will be measured by the percentage of patients whose cancer decreases in size on assessment. This will be measured as the sum of complete response and partial response.

Secondary Outcome Measures

Measure:Progression free survival (PFS)
Time Frame:At the end of Cycle 1 (each cycle is 28 days)
Safety Issue:
Description:Disease status will be assessed with comprehensive radiographic studies every 3 treatment cycles (12 weeks +/- 1 week), but the development of new signs or symptoms of disease in between scheduled evaluations may prompt off-schedule radiographic or non-radiographic evaluations. Disease status will be assessed based on RECIST 1.1 criteria for measurable and non-measurable disease.
Measure:Progression free survival (PFS)
Time Frame:At the end of Cycle 2 (each cycle is 28 days)
Safety Issue:
Description:Disease status will be assessed with comprehensive radiographic studies every 3 treatment cycles (12 weeks +/- 1 week), but the development of new signs or symptoms of disease in between scheduled evaluations may prompt off-schedule radiographic or non-radiographic evaluations. Disease status will be assessed based on RECIST 1.1 criteria for measurable and non-measurable disease.
Measure:Progression free survival (PFS)
Time Frame:At the end of Cycle 3 (each cycle is 28 days)
Safety Issue:
Description:Disease status will be assessed with comprehensive radiographic studies every 3 treatment cycles (12 weeks +/- 1 week), but the development of new signs or symptoms of disease in between scheduled evaluations may prompt off-schedule radiographic or non-radiographic evaluations. Disease status will be assessed based on RECIST 1.1 criteria for measurable and non-measurable disease.
Measure:Disease control rate (DCR)
Time Frame:greater than or equal to 24 weeks
Safety Issue:
Description:DCR will be measured by the percentage of patients whose cancer decreases in size or remains stable over the duration of the study. This will be measured as the sum of complete response, partial response, and stable disease for greater than or equal to 24 weeks.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Icahn School of Medicine at Mount Sinai

Trial Keywords

  • Platinum-resistant
  • Ovarian cancer
  • Ipatasertib
  • Paclitaxel
  • Recurrent

Last Updated

September 22, 2020